Inhibikase Therapeutics, Inc. (IKT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA, GA 30339 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 13,257 | 23,052 | 40,750 | |||
| Cash and cash equivalent | 9,170 | 7,190 | 40,750 | |||
| Short-term investments | 4,087 | 15,862 | ||||
| Prepaid expense | 220 | 1,118 | 107 | |||
| Other undisclosed current assets | 734 | 202 | ||||
| Total current assets: | 14,211 | 24,371 | 40,857 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 222 | 329 | ||||
| Property, plant and equipment | 73 | 237 | ||||
| Total noncurrent assets: | 296 | 565 | ||||
| Other undisclosed assets | 1,613 | |||||
| TOTAL ASSETS: | 14,507 | 24,936 | 42,470 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 2,907 | 3,550 | 3,806 | |||
| Accounts payable | 647 | 1,151 | 1,090 | |||
| Accrued liabilities | 2,260 | 2,398 | 2,716 | |||
| Debt | 150 | 146 | 249 | |||
| Other undisclosed current liabilities | 382 | |||||
| Total current liabilities: | 3,439 | 3,695 | 4,054 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 90 | 205 | ||||
| Operating lease, liability | 90 | 205 | ||||
| Total noncurrent liabilities: | 90 | 205 | ||||
| Total liabilities: | 3,529 | 3,901 | 4,054 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | 10,978 | 21,035 | 38,416 | |||
| Common stock | 6 | 25 | 25 | |||
| Additional paid in capital | 77,872 | 68,777 | 68,208 | |||
| Accumulated other comprehensive income (loss) | 1 | 105 | ||||
| Retained earnings (accumulated deficit) | (66,901) | (47,872) | 29,818 | |||
| Other undisclosed equity, attributable to parent | (59,635) | |||||
| Total equity: | 10,978 | 21,035 | 38,416 | |||
| TOTAL LIABILITIES AND EQUITY: | 14,507 | 24,936 | 42,470 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 261 | 123 | 3,101 | ||
| Gross profit: | 261 | 123 | 3,101 | ||
| Operating expenses | (20,350) | (18,252) | (17,867) | ||
| Operating loss: | (20,090) | (18,129) | (14,766) | ||
| Interest and debt expense | (20) | ||||
| Loss from continuing operations: | (20,090) | (18,129) | (14,786) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (14,786) | |
| Net loss: | (20,090) | (18,129) | (14,786) | ||
| Other undisclosed net income attributable to parent | 1,061 | 74 | |||
| Net loss available to common stockholders, diluted: | (19,029) | (18,054) | (14,786) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (20,090) | (18,129) | (14,786) | ||
| Other comprehensive loss | (19,133) | (17,949) | |||
| Comprehensive loss, net of tax, attributable to parent: | (39,223) | (36,078) | (14,786) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.